ClinicalTrials.gg
RecruitingNCT07477197HIBR-ACHDUpdated Mar 17, 2026

Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders

An observational study in Adult Congenital Heart Disease, Pulmonary Hypertension and Connective Tissue Disease, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in United States. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Children's Hospital Medical Center, Cincinnati · Observational

How we know

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Heart Defects, Congenital by Children's Hospital Medical Center, Cincinnati — 4 open to participants now, 5 under way, 1 of them phase 3. Heart Defects, Congenital · Children's Hospital Medical Center, Cincinnati.

Started
2021
the only one that year
Observational
7 of 14
1 open now
Registered
13th of 14
by date

Among the 14 studies in Heart Defects, Congenital by Children's Hospital Medical Center, Cincinnati, this one is the only one that started in 2021, is one of 7 observational ones, and was the 13th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

4 of the 14 studies in Heart Defects, Congenital by Children's Hospital Medical Center, Cincinnati are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 16 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Heart Defects, Congenital by Children's Hospital Medical Center, Cincinnati, or all of them as a file.
02

Study summary

A repository of biospecimens and detailed phenotypic information collected longitudinally from adults with congenital heart disease and related conditions, with an aim to facilitate future research on biologic mechanisms of underlying disease, compensation and deterioration; biologic correlates of patient experience and functional status; associations between clinical characteristics and various biomarkers; and predictors of clinical outcomes.

Read the detailed description

The goals of this protocol are to collect, maintain, and manage tissue specimens of various types for adults with congenital heart disease, adults with related disorders, and a set of control participants. Ultimately, we plan to approach all clinical encounters for adults (≥16 years-old) in the Heart Institute (HI) - and, in the future with additional review, the cardiology departments of additional participating sites.

We will collect extensive data on all enrolled participants, and also collect information directly from participants (e.g., via surveys about symptoms and lifestyle, patient-reported outcome metrics) at baseline and on an ongoing basis (e.g. sequential outpatient visits and procedure encounters).

03

Conditions studied

  • Adult Congenital Heart Disease
  • Pulmonary Hypertension
  • Connective Tissue Disease
  • Other Cardiovascular Conditions

Keywords

  • ACHD
  • Adult Congenital Heart Disease
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will include individuals aged 16 years or older who are suspected of having or diagnosed with congenital heart disease (CHD), other cardiovascular disease, pulmonary hypertension, connective tissue disease, or a genetic condition; healthy volunteers, and comparison participants without CHD but with a diagnosis of heart failure or pulmonary hypertension.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Any person ≥ 16 years-old suspected of having or diagnosed with congenital heart disease (CHD), other cardiovascular disease (CVD), pulmonary hypertension, connective tissue disease, or genetic syndrome/diagnosis.
  2. Additionally, a cohort (Control group A) of control subjects will be enrolled, again ≥16 years-old, self-reported non-smokers without a known history of diabetes mellitus, myocardial infarction, stroke, heart failure, or chronic kidney disease. These controls will be either:

    1. A family member or other person accompanying a patient to a clinical encounter; or,
    2. A volunteer recruited via an advertisement; or,
    3. Another person who volunteers to enroll in HIBR-ACHD.
  3. A cohort (Control group B) of comparison subjects who do not have CHD, but have a diagnosis of heart failure or pulmonary hypertension.

Exclusion criteria

Exclusion Criteria:

  • Unable to provide /assent personally or via a legal guardian.
  • Considered unsafe to collect the biospecimen determined by either a clinical provider or an HIBR-ACHD investigator.
  • Overnight hospitalization for non-obstetric reason with discharge in the prior 30 days.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • No treatment
06

What researchers measure

Primary outcomes

  1. Successful establishment of biospecimen repository

    Defined as the number and type of biospecimens collected and successfully linked with corresponding clinical and phenotypic data.

    Time frame: Day 1

Secondary outcomes

  1. Longitudinal biospecimen availability

    Number of participants with repeated biospecimen collections across multiple timepoints.

    Time frame: Day 1

Other outcomes

  1. Event-based biospecimen collection completeness

    Availability of biospecimens collected before, during, and after defined clinical interventions (e.g., surgery, exercise testing).

    Time frame: Day 1

  2. Data completeness of linked clinical phenotypes

    Proportion of participants with complete longitudinal clinical, demographic, and phenotypic datasets suitable for research.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Jan 2050, 342 months after the start.

Of 178 non-industry observational studies under Heart Defects, Congenital, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 83. This study's planned 342 months is above that.

Counting every sponsor, half of 185 studies reached it within 44 months; a quarter within 17 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 17, 2026
StartActual
Jul 1, 2021
Primary completionEst.
Jan 1, 2050
CompletionEst.
Jan 1, 2050
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07477197
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Jul 1, 2021
Primary completion
Jan 1, 2050 (estimated)
Completion
Jan 1, 2050 (estimated)
Last update
Mar 17, 2026

Study contacts

Sasha Opotowsky, MD
Contact
sasha.opotowsky@cchmc.org
513-803-2243
Lindsay Fist
Contact
lindsay.fist@cchmc.org
Sasha Opotowsky
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion